» Articles » PMID: 35090178

Watch and Wait Strategy for Rectal Cancer: How Long Should We Wait for a Clinical Complete Response?

Overview
Date 2022 Jan 28
PMID 35090178
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The objective of this study was to determine how long to wait in locally advanced rectal tumor (LARC) patients who receive total neoadjuvant therapy (TNT) and achieve a clinical complete response (cCR), and to identify the clinical parameters that affect the waiting period for the watch-and-wait strategy (W &W).

Materials And Methods: The data of patients who achieved cCR between February 2015 and June 2020 were examined retrospectively. The week in which patients with cCR at the end of TNT achieved clearance was determined by reanalyzing recorded endoscopy video images. In the assessment at the time of the initial diagnosis, tumor characteristics, such as digital rectal examination findings, MRI stage, location with respect to the puborectalis muscle, annularity, and tumor size, were recorded prospectively.

Results: A total of 54 patients were included in this study. According to the MRI-T stage, 14 cases were cT3a, 22 were cT3b, and 18 were cT3c-T4. Forty-four percent of the cases achieved cCR at 8-10 weeks, 19% at 12-16 weeks, 20% at 16-22 weeks, and 17% at 20-26 weeks. Patients with tumors that were early MRI-T stage (cT3a), negative clinical circumferential resection margin, mobile, small (≤4 cm), located above the puborectalis muscle and showed <180 degrees annularity achieved cCR significantly earlier than those with other tumors (p<0.05).

Conclusion: In this study, cCR was achieved in less than half (44%) of the cases during the 8-10 week waiting period. In the W&W strategy, the initial assessment for cCR seems insufficient, and we may need to wait up to 26-30 weeks, especially in patients with advanced-stage tumors.

Citing Articles

Comparison of laparoscopic versus robot-assisted sugery for rectal cancer after neo-adjuvant therapy: a large volume single center experience.

Zhu H, Zou J, Pan H, Huang Y, Chi P BMC Surg. 2025; 25(1):98.

PMID: 40075413 PMC: 11899483. DOI: 10.1186/s12893-025-02764-5.


Is clinical complete response as accurate as pathological complete response in patients with mid-low locally advanced rectal cancer?.

Shadmanov N, Aliyev V, Piozzi G, Bakir B, Goksel S, Asoglu O Ann Coloproctol. 2025; 41(1):57-67.

PMID: 40044112 PMC: 11894943. DOI: 10.3393/ac.2024.00339.0048.


Significant Pathologic Response Following Neoadjuvant Therapy and Curative Resection in Patients With Rectal Cancer: Surgical and Oncological Outcomes From a Retrospective Cohort Study.

Shahabi F, Ansari M, Najafi Ghobadi K, Ghahramani A, Parandeh A, Saberi-Karimian M Cancer Rep (Hoboken). 2024; 7(11):e70041.

PMID: 39506816 PMC: 11541061. DOI: 10.1002/cnr2.70041.


Comparing total mesorectal excision with partial mesorectal excision for proximal rectal cancer: evaluating postoperative and long-term oncological outcomes.

Aliyev V, Shadmanov N, Piozzi G, Bakir B, Goksel S, Asoglu O Updates Surg. 2024; 76(4):1279-1287.

PMID: 39037685 DOI: 10.1007/s13304-024-01926-z.


Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.

Asoglu O, Bulut A, Aliyev V, Piozzi G, Guven K, Bakir B World J Surg Oncol. 2022; 20(1):358.

PMID: 36352416 PMC: 9646475. DOI: 10.1186/s12957-022-02816-7.